2022年11月10日 · NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models.

2023年11月14日 · NX-1607 is an oral small-molecule inhibitor of CBL-B that enhances innate and adaptive immune responses (Figure 1): − NX-1607 has demonstrated anti-tumor activity and long-term survival in murine models as a single agent and in combination with PD-1 antibodies.2,5

Here we describe the effects of NX-1607, an orally bioavailable intramolecular glue inhibitor of CBL-B, on primary human T and NK cells and assess NX-1607 in combination with Rituximab in a murine xenograft model of Non-Hodgkin’s Lymphoma (NHL).

NX-1607 is an oral small-molecule inhibitor of CBL-B that has demonstrated anti-tumor activity and long-term survival in murine models as both a single agent and in combination with PD-1 antibodies.4,5 Further, NX-1607 elicits dose-dependent increases in cytokine secretion and proliferation in T-cell receptor-stimulated primary human T-cells ...

NX-1607 is a first-in-class, small molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), an E3 ligase that acts as a critical checkpoint in the immune system.

NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses

NX-1607 is a potent, reversible, and selective CBL-B inhibitor optimized for in vivo T cell activation. Multiple proprietary proximal biomarkers of CBL-B inhibition were identified in activated T cells.

NX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models

Single-Agent NX-1607 Induces Antitumor Response in Multiple Models Colorectal (CT26) Triple-Negative Breast (4T1)

Here, we characterized the antitumor and immune effects of NX-1607, a potent orally bioavailable inhibitor of CBL-B, when used as a single agent in a murine A20 syngeneic B cell lymphoma model and in combination with Rituximab in a Raji cell xenograft model of Non-Hodgkin's Lymphoma (NHL).